GSK Avandia For Alzheimer’s Could Be “The Most Important Asset” In Pipeline

GlaxoSmithKline's Avandia may become the most important product in the firm's pipeline if Phase III results show the type 2 diabetes drug to be effective at treating Alzheimer's disease, CEO J.P. Garnier said